DexCom (NASDAQ:DXCM) EVP Michael Jon Brown Sells 1,700 Shares

DexCom, Inc. (NASDAQ:DXCM) EVP Michael Jon Brown sold 1,700 shares of DexCom stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $64.85, for a total value of $110,245.00. Following the completion of the transaction, the executive vice president owned 112,904 shares of the company’s stock, valued at approximately $7,321,824.40. This trade represents a 1.48% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

DexCom Trading Up 0.5%

NASDAQ DXCM traded up $0.37 on Thursday, hitting $68.03. 145,578 shares of the stock were exchanged, compared to its average volume of 5,149,891. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.59 and a current ratio of 1.88. The stock has a fifty day moving average price of $70.53 and a two-hundred day moving average price of $68.22. The firm has a market capitalization of $26.18 billion, a P/E ratio of 32.34, a P/E/G ratio of 1.31 and a beta of 1.48. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $89.98.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, February 12th. The medical device company reported $0.68 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.03. DexCom had a net margin of 17.94% and a return on equity of 32.12%. The business had revenue of $1.26 billion for the quarter, compared to the consensus estimate of $1.25 billion. During the same quarter in the prior year, the firm posted $0.45 earnings per share. The business’s revenue for the quarter was up 13.1% on a year-over-year basis. Research analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on DXCM shares. Canaccord Genuity Group set a $95.00 price target on DexCom and gave the stock a “buy” rating in a research note on Friday, February 13th. Mizuho increased their target price on DexCom from $78.00 to $90.00 and gave the stock an “outperform” rating in a research note on Friday, February 13th. Citigroup lifted their target price on DexCom from $77.00 to $84.00 and gave the stock a “buy” rating in a research report on Wednesday, March 11th. BTIG Research restated a “buy” rating and issued a $85.00 price target on shares of DexCom in a report on Monday, March 9th. Finally, Leerink Partners reiterated an “outperform” rating and set a $92.00 price objective on shares of DexCom in a report on Tuesday, December 16th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, DexCom has an average rating of “Moderate Buy” and an average target price of $85.50.

Hedge Funds Weigh In On DexCom

Several institutional investors have recently made changes to their positions in DXCM. Vanguard Group Inc. grew its holdings in DexCom by 2.3% during the 3rd quarter. Vanguard Group Inc. now owns 49,456,043 shares of the medical device company’s stock worth $3,327,897,000 after acquiring an additional 1,133,638 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of DexCom by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 11,006,183 shares of the medical device company’s stock valued at $727,842,000 after purchasing an additional 42,411 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of DexCom by 6.9% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,999,057 shares of the medical device company’s stock worth $530,897,000 after purchasing an additional 516,526 shares during the period. Norges Bank purchased a new stake in shares of DexCom in the 4th quarter worth approximately $483,356,000. Finally, Invesco Ltd. boosted its stake in shares of DexCom by 14.8% during the fourth quarter. Invesco Ltd. now owns 5,315,367 shares of the medical device company’s stock valued at $352,781,000 after purchasing an additional 686,228 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.